Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Ovarian Cancer: Update Bulletin [July 2017]

Product Code:
Publication Date:
July 2017

This update bulletin presents key opinion leader (KOL) insights on recent events in the ovarian cancer treatment landscape. Topics covered include; the US approval and launch of Tesaro's PARP inhibitor Zejula (niraparib) for the maintenance treatment of recurrent ovarian cancer that is in complete or partial response to platinum-based chemotherapy; the Phase III ARIEL3 trial of Clovis’ PARP inhibitor Rubraca (rucaparib) meeting its primary endpoint of improved progression-free survival (PFS) in platinum-sensitive, high-grade ovarian, fallopian tube, or primary peritoneal cancer; and the new data from the Phase I/II ECHO-204 trial evaluating Incyte’s IDO1 inhibitor epacadostat plus Bristol-Myers Squibb’s PD-1 inhibitor Opdivo (nivolumab) in multiple solid tumours types, including ovarian cancer, presented at ASCO 2017.

Business Questions:

  • How do KOLs view the US approval of Tesaro's Zejula?
  • How will Zejula be used in the treatment of ovarian cancer? 
  • How will oncologists choose between the PARP inhibitors, and how is their comparative efficacy viewed, in the platinum-sensitive, maintenance setting?
  • How do the KOLs interpret the results of the ARIEL3 trial of Clovis’ Rubraca, and how do they view the overall significance of these data?
  • Where do KOLs see Rubraca fitting into the ovarian cancer treatment algorithm in the longer term? 
  • How do KOLs view the findings from the ECHO-204 trial of Bristol-Myers Squibb’s PD-1 inhibitor Opdivo in combination with Incyte’s IDO1 inhibitor epacadostat?
  • How do KOLs view the overall potential for combining an IDO inhibitor with a PD-1 inhibitor in the treatment of ovarian cancer and what could increase the chance of success for such combinations?


All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved